A Phase 2 interventional study of Clozapine in Schizophrenia, sponsored by Novartis. Completed. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-09-24.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 19 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Drug: Clozapine
Also known as: Clozaril
Adverse events during the long term treatment (until NDA approval)
Time frame: Baseline to 52 weeks
Vital signs at every 4 weeks
Time frame: Baseline to 52 weeks
Laboratory tests (hematology: at every 1 - 2 weeks, others: at every 4 weeks)
Time frame: Baseline to 52 weeks
ECG at every 12 weeks
Time frame: Baseline to 52 weeks
Echo cardiogram at every 24 weeks
Time frame: Baseline to 52 weeks
Changes in the symptoms of psychosis at every 8 weeks up to 52 weeks of treatment, thereafter at every 16 weeks
Time frame: Baseline to 52 weeks
Motor side effects at every 8 weeks up to 52 weeks of treatment, thereafter at every 16 weeks
Time frame: Baseline to 52 weeks
No study locations are listed for this record.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis